Novel Treatment Approaches in Higher-Risk Myelodysplastic Syndromes

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes.

In this video, Olatoyosi Odenike, MD, of the University of Chicago Medicine, reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes (MDS).

Odenike gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content
3 Things You Should Know About Hemolytic Anemias

3 Things You Should Know About Hemolytic Anemias

Catherine M. Broome, MD;Sigbjørn Berentsen, MD, PhD;Caroline Piatek, MD;Ilene Ceil Weitz, MD
December 20th 2024
Article

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Results from the phase 3 AVA-PED-301 trial support the FDA decision for avatrombopag in pediatric thrombocytopenia.

FDA Accepts NDA for Avatrombopag in Pediatric Thrombocytopenia

Roman Fabbricatore
December 17th 2024
Article

Results from the phase 3 AVA-PED-301 trial support the FDA decision for avatrombopag in pediatric thrombocytopenia.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis

Alex Biese
December 12th 2024
Article

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

NFKB1 Haplotype Boosts Response to Ropeginterferon in MPN Subtypes

NFKB1 Haplotype Boosts Response to Ropeginterferon in MPN Subtypes

Kyle Doherty
December 11th 2024
Article

NFKB1 rs230511 genetic variant improves treatment outcomes for patients with polycythemia vera and essential thrombocythemia.